NASDAQ:MTFBMOTIF BIO PLC/S Stock Price, Forecast & News

Add

Compare

Today's Range N/A

50-Day Range

$0.11

MA: $0.11▼

$0.11

52-Week Range N/A

Volume867,698 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
MOTIF BIO PLC/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, MOTIF BIO PLC/S has a potential upside of ∞ from its current price of $0.00.
Amount of Analyst Coverage
MOTIF BIO PLC/S has received no research coverage in the past 90 days.

2.3 Community Rank

Outperform Votes
MOTIF BIO PLC/S has received 240 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
MOTIF BIO PLC/S has received 275 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
MOTIF BIO PLC/S has received 53.40% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about MOTIF BIO PLC/S and other stocks. Vote “Outperform” if you believe MTFB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MTFB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
MOTIF BIO PLC/S does not currently pay a dividend.
Dividend Growth
MOTIF BIO PLC/S does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MOTIF BIO PLC/S insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for MOTIF BIO PLC/S are expected to grow in the coming year, from ($1.60) to ($1.35) per share.

Overall Beat the Market Rank^™

1.29 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MTFB

Previous Symbol

CUSIPN/A

CIK1674657

Webwww.motifbio.com

Phone212-210-6248

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.60) per share

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees7

Outstanding Shares14,830,000

Market CapN/A

Next Earnings DateN/A

OptionableNot Optionable

Receive MTFB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTFB and its competitors with MarketBeat's FREE daily newsletter.

MOTIF BIO PLC/S (NASDAQ:MTFB) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of MOTIF BIO PLC/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MOTIF BIO PLC/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MOTIF BIO PLC/S.

What price target have analysts set for MTFB?

1 analysts have issued 1 year price objectives for MOTIF BIO PLC/S's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate MOTIF BIO PLC/S's share price to reach $5.00 in the next year. View analysts' price targets for MOTIF BIO PLC/S.

Has MOTIF BIO PLC/S been receiving favorable news coverage?

News headlines about MTFB stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MOTIF BIO PLC/S earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutMOTIF BIO PLC/S.

Who are some of MOTIF BIO PLC/S's key competitors?

Some companies that are related to MOTIF BIO PLC/S include 89bio (ETNB), Advanz Pharma (CXRXF), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM), Myrexis (MYRX), NeuroVive Pharmaceutical (NEVPF) and Pivot Pharmaceuticals (PVOTF). View all competitors.

What other stocks do shareholders of MOTIF BIO PLC/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MOTIF BIO PLC/S investors own include Sorrento Therapeutics (SRNE), Allergan (AGN), Ampliphi Biosciences (APHB), Neurocrine Biosciences (NBIX), Canopy Growth (CGC), Forward Pharma A/S (FWP), Novartis (NVS), SDX Energy (SDX), Adaptimmune Therapeutics (ADAP) and Allena Pharmaceuticals (ALNA).

Who are MOTIF BIO PLC/S's key executives?

MOTIF BIO PLC/S's management team includes the following people:

Dr. Graham George Lumsden, CEO & Exec. Director (Age 59)
Mr. Jonathan E. Gold, CFO & Exec. Director (Age 46)
Dr. David B. Huang, Chief Medical Officer (Age 44)
Mr. Robert Dickey IV, Advisor (Age 63)
Laurie Doyle, Head of Investor Relations & Corp. Communications

When did MOTIF BIO PLC/S IPO?

(MTFB) raised $17 million in an initial public offering on Friday, November 18th 2016. The company issued 2,400,000 shares at $6.98 per share. H.C. Wainwright & Co. served as the underwriter for the IPO.

What is MOTIF BIO PLC/S's stock symbol?

MOTIF BIO PLC/S trades on the NASDAQ under the ticker symbol "MTFB."

How do I buy shares of MOTIF BIO PLC/S?

Shares of MTFB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is MOTIF BIO PLC/S?

MOTIF BIO PLC/S has a market capitalization of $0.00. MOTIF BIO PLC/S employs 7 workers across the globe.

What is MOTIF BIO PLC/S's official website?

The official website for MOTIF BIO PLC/S is www.motifbio.com.

How can I contact MOTIF BIO PLC/S?

MOTIF BIO PLC/S's mailing address is 201 TEMPLE CHAMBERS 3-7 TEMPLE AVENUE, LONDON X0, EC4Y0DT. The company can be reached via phone at 212-210-6248 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

NASDAQ:MTFBMOTIF BIO PLC/S Stock Price, Forecast & News

Adding

Adding

Adding MOTIF BIO PLC/S

Beat the Market (BTM) Rank™